Importantly, OX-AAT, produced from recombinant WT-AAT or commercially available respreeza, a drug that is repetitively given to patients with AAT-deficiency, did not diminish mPR3 or neutrophil activation by PR3-ANCA (Figure 7, B and C). The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.